Biotech entity
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention Cannabis Hyperemesis Syndrome, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention CDC National Center for Injury Prevention and Control, all published on August 7, 2026.
Last mentioned: Aug 7, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention Cannabis Hyperemesis Syndrome, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention CDC National Center for Injury Prevention and Control, all published on August 7, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CDC National Center for Injury Prevention and Control. Shared-story counts are live from our verified record — not editorial picks.
With 2.75 million suffering from cannabis hyperemesis syndrome and a 16% jump in ED diagnoses after a new ICD code, an underserved patient population emerges. Biopharma companies can explore targeted therapies for CHS, a condition currently managed only with abstinence and supportive care, presenting a significant unmet medical need.
Source: troyrecord.com · MedPage Today
CDC National Center for Injury Prevention and Control is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
